Enabling earlier, more accurate diagnosis of bowel cancer
Early detection of bowel cancer is vital, yet current diagnostic pathways can be slow, invasive, and difficult to access – creating barriers that can lead to delayed diagnosis and poorer outcomes.
The CanSense-CRC test is a novel, low‑cost blood test that uses Raman spectroscopy and machine learning to accurately detect early‑stage bowel cancer. Its reagent‑free approach offers a sustainable, scalable solution that removes common equality, diversity, and inclusivity barriers seen in traditional screening methods.
CanSense‑CRC improves patient outcomes by enabling faster, more accessible and more accurate detection. It reduces the need for invasive procedures, supports earlier intervention and improves diagnostic pathways across NHS systems.
To support development, our HRC:
- Accelerated adoption of innovative diagnostics within NHS pathways
- Provided multi‑disciplinary expertise in bringing novel technologies into real‑world care
- Linked to NHS partners to understand diagnostic needs and integration challenges
- Supported evidence generation to drive uptake and demonstrate clinical value
